News

HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.1-5

These countries include Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia. With this distributorship in place, Iclusig will be available to patients with resistant and intolerant

As part of the deal, Knight will pay around $1.75m cash as well as offer additional funding to further develop new pharmaceutical products. The deal will see establishment

Amitiza is a prostone and a locally acting chloride channel activator indicated in the US to treat CIC and OIC in adults. The company said that the effectiveness

Bekinda (RHB-102) is a proprietary once-daily oral pill formulation of the antiemetic drug ondansetron. The UK MHRA has started the formal review process for the MAA on 30

The agreement granted Takeda exclusive rights to market ferumoxytol in Canada, EU and Switzerland, as well as certain other geographic territories As part of the termination deal, AMAG

The drug is indicated for use in adults to manage pain, by taking it alone or in combination with opioid analgesics. Hospira senior vice-president and chief scientific officer

FDA has approved the new drug application (NDA) for Namzaric to treat moderate to severe dementia of the Alzheimer’s type in patients stabilised on memantine hydrochloride and donepezil

After securing clinical trial application (CTA) regulatory approval, the company plans to conduct a Phase I trial to assess the safety, tolerability and dose escalation of Anatabine Citrate